Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients

Cancer Immunology, Immunotherapy

Volumn 55, Issue 8, 2006, Pages 973-980

  Watson, Nicholas F S ^a,b   Durrant, Lindy G ^a   Madjd, Zahra ^a   Ellis, Ian O ^c   Scholefield, John H ^b   Spendlove, Ian ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

^c NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

CD59; Colorectal cancer; Prognostic factor; Tissue microarray

Indexed keywords

CD59 ANTIGEN; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT REGULATORY PROTEIN; MEMBRANE PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CELL PROTECTION; CLINICAL FEATURE; COLORECTAL CANCER; COLORECTAL TUMOR; COMPLEMENT ACTIVATION; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNE SYSTEM; IMMUNOSURVEILLANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; TREATMENT PLANNING; TUMOR CLASSIFICATION; TUMOR ESCAPE; TUMOR GROWTH; TUMOR LOCALIZATION;

ADENOCARCINOMA; AGED; ANTIGENS, CD59; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33646369422     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0055-0     Document Type: Conference Paper

References (32)

1. Bjorge L, Jensen TS, Matre R (1996) Characterisation of the complement-regulatory proteins decay accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line. Cancer Immunol Immunother 42:185-192
2. Bjorge L, Vedeler CA, Ulvestad E, Matre R (1994) Expression and function of CD59 on colonic adenocarcinoma cells. Eur J Immunol 24:1597-1603
3. Camp RL, Charette LA, Rimm DL (2000) Validation of tissue microarray technology in breast carcinoma. Lab Invest 80:1943-1949
4. Donin N, Jurianz K, Ziporen L, Schultz S, Kirschfink M, Fishelson Z (2003) Complement resistance of human cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin Exp Immunol 131:254-263
5. Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Ann Rev Immunol 22:329-360
6. Durrant LG, Chapman MA, Buckley DJ, Spendlove I, Robins RA, Armitage NC (2003) Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol Immunother 52:638-642
7. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M (2003) Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 40:109-123
8. Gelderman KA, Kuppen PJ, Bruin W, Fleuren GJ, Gorter A (2002) Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma. Eur J Immunol 32:128-135
9. Gelderman KA, Tomlinson S, Ross GD, Gorter A (2004) Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 25:158-164
10. Gorter A, Meri S (1999) Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today 20:576-582
11. Hosch SB, Scheunemann P, Luth M, Inndorf S, Stoecklein NH, Erbersdobler A, Rehders A, Gundlach M, Knoefel WT, Izbicki JR (2001) Expression of 17-1A antigen and complement resistance factors CD55 and CD59 on liver metastases in colorectal cancer. J Gastrointest Surg 5:673-679
12. Inoue T, Mizuno M, Uesu T, Ueki T, Tsuji T (1994) Distribution of complement regulatory proteins, decay-accelerating factor, CD59/homologous restriction factor 20 and membrane cofactor protein in human colorectal adenoma and cancer. Acta Med Okayama 48:271-277
13. Inoue T, Yamakawa M, Takakhashi T (2002) Expresssion of complement regulating factors in gastric cancer cells. J Clin Pathol Mol Pathol 55:193-199
14. Juhl H, Helmig F, Baltzer K, Kalthoff H, Henne-Bruns D, Kremer B (1997) Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A. J Surg Oncol 64:222-230
15. Jurianz K, Maslak S, Garcia-Schuler H, Fishelson Z, Kirschfink M (1999) Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2. Immunopharmacology 42:209-218
16. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high throughput molecular profiling of tumour specimens. Nat Med 4:844-847
17. Koretz K, Bruderlein S, Henne C, Moller P (1993) Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium. Br J Cancer 68:926-931
18. Lachmann PJ (1991) The control of homologous lysis. Immunol Today 12:312-315
19. Madjd Z, Durrant LG, Bradley R, Spendlove I, Ellis IO, Pinder SE (2004) Loss of CD55 is associated with aggressive breast tumors. Clin Cancer Res 10:2797-2803
20. Madjd Z, Durrant LG, Pinder SE, Ellis IO, Ronan J, Lewis S, Rushmere NK, Spendlove I (2005) Do poor-prognosis breast tumors express membrane cofactor proteins (CD46)? Cancer Immunol Immunother 54:149-156
21. Madjd Z, Pinder SE, Paish C, Ellis IO, Carmichael J, Durrant LG (2003) Loss of CD59 expression in breast tumors correlates with poor survival. J Pathol 200:633-639
22. Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG (2005) Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer (e-pub ahead of print)
23. Maio M, Brasoveanu LI, Coral S, Sigalotti L, Lamaj E, Gasparollo A, Visintin A, Altomonte M, Fonsatti E (1998) Structure, distribution, and functional role of protectin (CD59) in complement-suceptibility and in immunotherapy of human malignancies. Int J Oncol 13:305-318
24. Meri S, Waldmann H, Lanchman PJ (1991) Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissue. Lab Invest 65:532-537
25. Muller-Eberhard HJ (1986) The membrane attack complex of complement. Ann Rev Immunol 4:503-528
26. National Institute for Clinical Excellence (2004) Improving outcomes in colorectal cancers: manual update. NICE, London
27. Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, Dalmasso AP (1996) Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay accelerating factor), and CD59 (protectin). Am J Pathol 149:129-142
28. Quinn M, Babb P, Brock A, Kirby L, Jones J (2001) Cancer trends in England and Wales 1950-1999. The stationary office, London
29. Schmitt CA, Schwaeble W, Wittig BM, Meyer zum Buschenfelde KH, Dippold WG (1999) Expression and regulation by interferon-γ of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumors. Eur J Cancer 35:117-124
30. Thorsteinsson L, O'Dowd G, Harrington PM, Johnson PM (1998) The complement regulatory proteins CD46 and CD59 but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumor tissues. APMIS 106:869-878
31. Torhorst J, Bucher C, Kononen J, Hass P, Zuber M, Kochli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP, Sauter G (2001) Tissue microarrays for the rapid linking of molecular changes to clinical endpoints. Am J Pathol 159:2249-2256
32. Xu C, Jung M, Burkhardt M, Stephan C, Schnorr D, Loening S, Jung K, Dietel M, Kristiansen G (2005) Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy. Prostate 62:224-232